Halozyme Therapeutics (HALO) PT Raised to $26 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Halozyme Therapeutics (HALO) Raised to $19 at Piper Jaffray
March 3, 2015 7:17 AM ESTPiper Jaffray analyst Charles Duncan reiterated an Overweight rating and boosted his price target on Halozyme Therapeutics (NASDAQ: HALO) to $19.00 (from $17.00) following Q4 results.. The firm said proprietary program visibility should increase in 2015.
Duncan commented, "On Monday AMC, Halozyme reported 4Q/FY14 results, reiterating 2015... More
Halozyme Therapeutics (HALO) Tops Q4 EPS by 3c; Guides FY15 Revs
March 2, 2015 4:17 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $30.38 million versus the consensus estimate of $25.6 million.
Halozyme Therapeutics sees FY2015 EPS of $85.00-$95.00, versus the consensus of $97.70.
For earnings history and... More
